A Phase IIa, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients

Trial Profile

A Phase IIa, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jan 2011

At a glance

  • Drugs Lanicemine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Nov 2007 Status changed from recruiting to completed.
    • 17 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top